Among patients with mildly reduced or heart failure and preserved ejection fraction (HFpEF) both SGLT2 inhibitors and more recently, steroidal mineralocorticoid receptor antagonists (MRAs) have been shown to reduce the rate of hospitalization for heart failure.26 The gene discussed is NR3C2; the disease is heart failure.